A worldwide, multicenter, double-blind, parallel study to evaluate the tolerability of MK-0524A [niacin/laropiprant] versus niacin extended-release
Phase of Trial: Phase III
Latest Information Update: 21 Feb 2017
At a glance
- Drugs Niacin/laropiprant (Primary) ; Niacin
- Indications Lipid metabolism disorders
- Focus Adverse reactions; Registrational
- Sponsors Merck & Co
- 01 Apr 2008 Results were presented at the 57th Annual meeting of the American College of Cardiology.
- 07 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov.
- 15 Nov 2006 Status change